Inhaler monitoring company Propeller Health has announced that it will develop a sensor for GSK’s Ellipta dry powder inhaler for use in gathering inhaler usage data during clinical trials. GSK also has the option to obtain exclusive rights for a version of the sensor to be included with its marketed Ellipta products.
Propeller’s monitoring system was approved by the FDA for use with the Diskus and Respimat inhalers in July 2015, and its system for tracking MDI usage was approved in 2014.
Propeller Health CEO and Co-Founder David Van Sickle said, “We are pleased to announce a collaboration with GSK, a global leader in the treatment of respiratory disease. Together we aim to combine our expertise to empower patients and positively impact care.”
GSK Senior VP of Respiratory R&D Dave Allen commented, “We continue to find new and better ways to conduct clinical trials by exploring novel patient centered outcomes through strategic collaborations. Using innovative sensor technology to improve the quality of adherence data collected during our studies will advance our understanding of disease and inform our decision-making in the development of new medicines.”
Read the Propeller Health press release.
